Auszug
Cholinesterasehemmer und Memantin zeigen 2006 einen weiteren Verordnungszuwachs und haben jetzt einen Anteil von 50% am Verordnungsvolumen der Antidementiva erreicht. Traditionelle Antidementiva (Sekalealkaloide, Piracetam, Ginkgoextrakt) haben dagegen ihren rückläufigen Trend fortgesetzt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363:2105–2115.
Aguero-Torres H, Fratiglioni L, Winblad B (1998): Natural history of Alzheimer’s disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry 13: 755–766.
Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115.
Birks J (2006): Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25;(l):CD005593.
Birks J, Grimley Evans J (2006): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003120.
Birks J, Harvey RJ (2006): Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD001190.
Birks J, Iakovidou V, Tsolaki M (2000): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2: CD001191.
Blennow K, de Leon MJ, Zetterberg H (2006): Alzheimer’s disease. Lancet 368: 387–403.
Committee for Proprietary Medicinal Products (CPMP) (1998): Note for guidance on medicinal products in the treatment of Alzheimer’s disease.
Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65.
Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M (1993): Longterm and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305.
Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403.
Dodel RC, Hampel H, Du Y (2003): Immunotherapy for Alzheimer’s disease. Lancet Neurology 2: 215–220.
Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A et al. (2004): Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75: 1472–1474.
Dyer C (2007): NICE faces legal challenge over Alzheimer’s drug. BMJ 334: 654–655.
Fioravanti M, Flicker L (2001): Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001 (4): CD003159.
Flicker L, Grimley Evans G (2001): Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011.
Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005): Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563–1572.
Gaitz CM, Varner RV, Overall JE (1977): Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2007): Nutzenbewertung von Cholinesterasehemmern bei Patienten mit Alzheimer Demenz, auch im Vergleich mit anderen Therapieoptionen. Im Internet unter: www.iqwig.de/download/A05-19A_Abschlussbericht_Cholinesterasehemmer_bei_Alzheimer_Demenz.pdf
In’t Veld BA, Riutenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001): Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345: 1515–1521.
Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D (1978): Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462.
Lopez-Arrieta JM, Birks J (2002): Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002; (3): CD000147.
Loy C, Schneider L (2006): Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD001747.
Marin DB, Davis KL (1995): Experimental therapeutics. In: Bloom FE, Kupfer DJ (eds): Psychopharmacology: The fourth generation of progress. Raven Press Ltd, New York, pp 1417–1426.
McShane R, Areosa Sastre A, Minakaran N (2006): Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154.
Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283: 1007–1015.
National Institute for Health and Clinical Excellence (2006): NICE technology appraisal guidance 111: Donepezil, galantamine, rivastigmine (review) andmemantine for the treatment of Alzheimer’s disease. Includes a review of NICE technology appraisal guidance 19. Im Internet: http://guidance.nice. org.uk/TAlll/ guidance/pdf/English
Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weiler RO (2003): Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med 9: 448–452.
Olin J, Schneider L, Novit A, Luczak S (2001): Hydergine for dementia. Cochrane Database Syst Rev. 2001;(2):CD000359.
Orgogozo J-M, Gilman S, Dartigues JE, Laurent B, Puel M, Kirby LC et al. (2003): Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46–54.
Ortho-McNeil Neurologics (2005): Important Prescribing Information 31.03.2005. Internet: http://www.fda.gov/medwatch/SAFETY/2005/reminylDDLmarch.pdf
Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D (2005): Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36: 619–624.
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005): Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388.
Reines SA, Block GA, Morris JC, Liu G, Nessly ML et al (2004): Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al for the Members of the Alzheimer’s Disease Cooperative Study (1997): A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222.
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB Ockene JK et al for the WHIMS Investigators (2003): Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651–2662.
Thompson TL II, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL (1990): Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 323:445–448.
Walker LC, Ibegbu CC, Todd CW, Robinson HL, Jucker M, LeVine H 3rd, Gandy S (2005): Emerging prospects for the disease-modifying treatment of Alzheimer’s disease. Biochem Pharmacol 69: 1001–1008.
Winblad B (2005): Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11: 169–182.
Winblad B, Poritis N (1999): Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriat Psychiatry 14: 135–146.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2008). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-540-72548-0_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72547-3
Online ISBN: 978-3-540-72548-0
eBook Packages: Medicine (German Language)